My site

Supports 5V systems in a small package especially suitable for mobile devices

TOKYO - Tuesday, December 11th 2012

(BUSINESS WIRE/ ME Newswire)-- Toshiba Corporation (TOKYO:6502) has launched a new series of CMOS multi-function gate logic devices that support 5V systems and that are housed in small packages suitable for mobile devices such as mobile phones, smartphones, tablet PCs, digital cameras and digital video cameras.

Multifunction gate logic ICs allows users to select one from multiple gate functions, depending on the processing status of input signals. The new SZ series, based on Toshiba's existing low voltage drive multi-function gate logic SP series, extends support to 5V systems. Also added to the line-up is the SZT Series, a TTL-input-type device that secures level translation from low-voltage systems. A Schmitt trigger circuit is used for all input. The new products are in small MP6 packages (1.0mm x 1.45mm x 0.55mm) that support the requirements of sm ... Read more »

INGELHEIM, Germany - Tuesday, December 11th 2012 [ME NewsWire]

    Phase II study demonstrated higher rates of objective response and an improvement in event free survival (EFS) in patients with acute myeloid leukaemia (AML) receiving volasertib* in combination with low-dose cytarabine (LDAC) versus LDAC alone
    Phase III study of volasertib* in AML is planned to be initiated in early 2013

(BUSINESS WIRE)-- For NON-US media only

New positive Phase II results from an interim analysis of the randomised Phase I/II study involving the company’s investigational haematology/oncology compound volasertib* in newly diagnosed patients with acute myeloid leukemia (AML) considered ineligible for intensive remission induction therapy were presented at the 54th American Society of Hematology (ASH) annual meeting in Atlanta, USA. In this study, higher rates of objective response (primary endpoint) and an improvement in event free survival (secon ... Read more »

ATLANTA - Tuesday, December 11th 2012 [ME NewsWire]

(BUSINESS WIRE)-- Millennium: The Takeda Oncology Companywith its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today announced the presentation of data from a phase 1 study investigating once a week MLN9708 in patients with relapsed or refractory systemic light-chain (AL) amyloidosis. The primary objectives of this open-label, dose-escalation, phase 1 study were to determine the safety, tolerability, and maximum tolerated dose (MTD) of MLN9708 in patients with relapsed or refractory AL, and to determine the dose for future development. Once the MTD was reached, two expansion cohorts were enrolled, one with proteasome inhibitor-naïve patients (n=5) and one with proteasome inhibitor-exposed patients (n=12). The data were presented at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition held December 8-11, 2012 in Atlanta, GA.

"Preliminary evidence of hematologic responses and early ... Read more »

INGELHEIM, Germany - Monday, December 10th 2012 [ME NewsWire]

    In RE-LY®, patients had better survival prognosis and spent less time in intensive care following a major bleed with Pradaxa® (dabigatran etexilate) than with warfarin
    Data provide further support for the favourable safety profile of Pradaxa®
    Presentation at American Society of Hematology (ASH) 2012 highlighted as ‘Best of ASH’

(BUSINESS WIRE)-- For Non-US, Non-UK & Non-Canadian Media Only

Results from a new post-hoc analysis of the landmark RE-LY®i trial show that in patients experiencing a major bleeding event, treatment with Pradaxa® (dabigatran etexilate) was associated with lower mortality and a shorter length of stay in intensive care compared to warfarin. In a pooled post-hoc analysis of five Phase III trials with Pradaxa®, the data show a clear trend towards a better prognosis after a major bleed with Prada ... Read more »

ME Newswire / Business Wire

VILLEJUIF, France - Monday, December 10th 2012

Worldwide Innovative Network (WIN) in personalized cancer medicine consortium today proudly announced that Pfizer, Inc(NYSE:PFE) is the first pharmaceutical company to become a member of the consortium. Founded on the recognition that greater success can be achieved through collaboration than any organization can achieve alone, the WIN Consortium is a global network of leading academic, industry, and patient advocacy organizations working to make personalized cancer care a reality for patients worldwide.

Pfizer’s strong corporate commitment to the development of drugs using a precision medicine approach, coupled with the company’s deep breadth of experience in the development of oncology therapeutics, strategically align the company’s goals and capabilities with the mission of the WIN Consortium. As the newest member of the consortium, Pfizer will play an integral role in shaping the future ... Read more »

ATLANTA - Sunday, December 9th 2012 [ME NewsWire]

MLN9708: First oral proteasome inhibitor to enter clinical evaluation in front-line multiple myeloma in combination with lenalidomide, dexamethasone

(BUSINESS WIRE)-- Millennium: The Takeda Oncology Companywith its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today reported data from a phase 1 / 2 study of once a week investigational MLN9708 in combination with standard dose lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma (MM). The previously reported phase 1 portion of the study was a dose escalation study to determine the safety, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of MLN9708 in combination with lenalidomide and dexamethasone. The primary objectives of the ongoing phase 2 portion of the study are to determine the combined complete and very good partial response rates (≥VGPR), safety and tolerability. Secondary objectives include overall resp ... Read more »

ME Newswire / Business Wire

STARNBERG, Germany - Saturday, December 8th 2012

Maynards Europe GmbH, Hilco Industrial Europeand Heritage Global Partners Europetoday announced that they have been retained by Schüco International, a worldwide pioneer in glass-glass photovoltaics (PV), including unique building-integrated (BIPV), to jointly manage a series of sales for its state-of-the-art solar module production and related capital assets located at Germany-based plants in Osterweddingenand Großröhrsdorf,and an R&D Center in Bielefeld.

"We are pleased that Schüco TF GmbH & Co. KG and Malibu Gmbh & Co. KG have selected our Joint Venture Team to maximize the value of their assets. We believe our global presence and familiarity with the international marketplace, paired with our expert local knowledge, will attract significant interest from worldwide buyers for this wealth of high quality equipment,” stated Daniel Kröger, Managing Director of Maynards Europe.< ... Read more »

A Norwegian study recently showed that better energy labelling could help European consumers save both money and 10 megatons of CO2 every year.

OSLO, Norway - Friday, December 7th 2012 [ME NewsWire]

(BUSINESS WIRE)-- In cooperation with Scandinavia’s biggest electrical retail chain, Elkjøp, the Norwegian NGO GreeNudge informed customers about total lifetime costs of household appliances. We did this by adding a second price tag to the conventional sales price: lifetime energy cost. We used this cost information to nudge customers to buy more energy efficient products.

GreeNudge initiated and funded the study, which was conducted by researchers from CICERO Center for International Climate and Environmental Research - Oslo. The results were published in the Journal of Consumer Policy. The combined effect of lifetime cost labelling of tumble driers, and training sales staff to promote energy efficient products, was a 5 % net reduction in energy use from the appliance ... Read more »

MCLEAN, Va - Friday, December 7th 2012 [ME NewsWire]

(BUSINESS WIRE)-- Hilton Worldwide issued the following statement today from President & CEO Christopher J. Nassetta:

"Hilton Worldwide commends the U.S. Senate for voting to extend Permanent Normal Trade Relations (PNTR) to Russia, which is very much in the interest of the United States and American companies conducting business there. PNTR will enhance transparency and rule of law in Russia and allow international service providers like Hilton Worldwide to compete on a fair playing field.”

Russia has become Hilton Worldwide’s fastest growing market in Europe, after opening its first hotel in Russia only four years ago. The total number of the company’s hotels operating or under development in Russia has already reached 32.

Hilton Worldwide is committed to playing an active role in supporting Russian tourism over the long term. This year the company conducted an in-depth, independent study titled, "Ba ... Read more »